Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDOX-AHF
NCT05613218Phase 3Completed
- Sponsor
- Rigshospitalet
- Start
- Feb 2024
- Primary completion
- Feb 2026
- Modality
- Inhalation Devices
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of oxygen in Acute Heart Failure (AHF), Pulmonary edema and hypoxemia, sponsored by Rigshospitalet. Primary endpoint: Change in pulmonary parenchymal fluid content at 24 hours. Started Feb 2024; status: completed.
02
Drugs
oxygen
03
Conditions
Acute Heart Failure (AHF)Pulmonary edemahypoxemia
Beyond the preview
Go deeper on NCT05613218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05613218.